These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2374176)

  • 1. Lung cancer and the debrisoquine metabolic phenotype.
    Caporaso NE; Tucker MA; Hoover RN; Hayes RB; Pickle LW; Issaq HJ; Muschik GM; Green-Gallo L; Buivys D; Aisner S
    J Natl Cancer Inst; 1990 Aug; 82(15):1264-72. PubMed ID: 2374176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
    Caporaso N; Hayes RB; Dosemeci M; Hoover R; Ayesh R; Hetzel M; Idle J
    Cancer Res; 1989 Jul; 49(13):3675-9. PubMed ID: 2731181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine metabolism and lung cancer risk.
    Shaw GL; Falk RT; Deslauriers J; Frame JN; Nesbitt JC; Pass HI; Issaq HJ; Hoover RN; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):41-8. PubMed ID: 7894323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
    Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
    Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
    Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
    Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphic oxidation of debrisoquine in bladder cancer.
    Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
    Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.
    Green-Gallo LA; Buivys DM; Fisher KL; Caporaso N; Slawson RG; Elias G; Didolkar MS; Ivusich WJ; Resau JH
    Cancer; 1991 Jul; 68(1):206-10. PubMed ID: 2049747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.
    Ayesh R; Idle JR; Ritchie JC; Crothers MJ; Hetzel MR
    Nature; 1984 Nov 8-14; 312(5990):169-70. PubMed ID: 6504125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
    Ritchie JC; Idle JR
    IARC Sci Publ; 1982; (39):381-94. PubMed ID: 7152615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
    Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
    Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debrisoquine metabolism and genetic predisposition to lung cancer.
    Law MR; Hetzel MR; Idel JR
    Br J Cancer; 1989 May; 59(5):686-7. PubMed ID: 2736200
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
    Duche JC; Joanne C; Barre J; de Cremoux H; Dalphin JC; Depierre A; Brochard P; Tillement JP; Bechtel P
    Br J Clin Pharmacol; 1991 May; 31(5):533-6. PubMed ID: 1888620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.